Physician profile
Sharon Mayers
NPI 1255972253
$5,311.45
in general payments reported to CMS, 2019-2025
31 companies · $648 in 2025
The $648 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,444 · 2022: $266 · 2023: $629 · 2024: $2,325 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742 · Travel and Lodging: $760 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.48 |
| Travel and Lodging | $760.33 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $1,618.59 | 2024 | Prevena, 3m Skin and Nasal Antiseptic, Spoton |
| Phathom Pharmaceuticals, INC. | $499.29 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $481.37 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $420.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $299.07 | 2021-2025 | Airsupra |
| Novo Nordisk INC | $293.37 | 2021-2025 | Wegovy |
| Astellas Pharma US INC | $251.94 | 2021-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $176.40 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $167.77 | 2021 | |
| Urovant Sciences INC | $124.65 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $121.48 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $117.45 | 2023 | Quviviq |
| Cvrx, INC. | $114.17 | 2025 | Barostim Neo System |
| Eisai INC. | $111.61 | 2021 | |
| Glaxosmithkline, LLC. | $93.81 | 2021-2025 | Trelegy Ellipta, Arexvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $92.26 | 2021-2022 | |
| Amgen INC. | $58.45 | 2021 | |
| Amarin Pharma, INC. | $37.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.09 | 2021 | |
| Ironshore Pharmaceuticals INC. | $26.45 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.02 | 2025 | Strensiq |
| Sunovion Pharmaceuticals INC. | $19.38 | 2021 | |
| Boston Scientific Corporation | $17.80 | 2022 | |
| Exact Sciences Corporation | $17.40 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $16.41 | 2025 | |
| Smith+Nephew, INC. | $14.96 | 2024 | Collagenase Santyl |
| Arbor Pharmaceuticals, INC. | $13.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.63 | 2021 | |
| Dexcom, INC. | $13.36 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $11.69 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Mayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.